Spyre Therapeutics, Inc. (SYRE) Key Metrics
SYRE valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $7.47B
- Enterprise value
- $6.78B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 650.2
- Price / book
- 8.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 3.11
SYRE key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsSYRE valuation Price multiples at each fiscal year-end price.
Price / book+38.8%
2.9
2025 · hover or tap a bar for each year
20162025
Free cash flow yield+6.3 pts
−8.1%
2025 · hover or tap a bar for each year
20162025
SYRE returns How much profit the business earns on the capital it uses.
Return on equity+34.1 pts
−25.2%
2025 · hover or tap a bar for each year
20162025
Return on assets+21.4 pts
−22.4%
2025 · hover or tap a bar for each year
20162025
Asset turnover−100.0%
0.00
2025 · hover or tap a bar for each year
20162025
SYRE per-share figures Results divided by the shares outstanding at year-end.
Revenue per share−100.0%
$0.00
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$2.42
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$2.64
2025 · hover or tap a bar for each year
20162025
Book value per share+1.4%
$11.17
2025 · hover or tap a bar for each year
20162025
Shares outstanding+36.2%
64.1M
2025 · hover or tap a bar for each year
20162025
SYRE financial health Debt, liquidity and how easily interest is covered.
Net debt−$238.0M
−$756.5M
2025 · hover or tap a bar for each year
20162025
Current ratio+17.8%
13.25
2025 · hover or tap a bar for each year
20162025
SYRE efficiency & capital use Working capital cycle and where the cash goes.
Days payables outstanding−286 days
10 days
2025 · hover or tap a bar for each year
20162025
SYRE valuation history
Fiscal year-endToday10-year median
SYRE returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SYRE debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SYRE price vs earnings per share
Share price at year-endEPS (right axis)
SYRE key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $2.10B | $1.09B | — | — | — | — | — | — | — | — |
| Enterprise value | $1.34B | $576.3M | — | — | — | — | — | — | — | — |
| Price / book | 2.9 | 2.1 | — | — | — | — | — | — | — | — |
| EV / sales | — | 650.4 | — | — | — | — | — | — | — | — |
| Earnings yield | −7.4% | −19.0% | — | — | — | — | — | — | — | — |
| Free cash flow yield | −8.1% | −14.4% | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $32.76 | $23.28 | $21.52 | $11.25 | $118.75 | $196.75 | $191.00 | $187.25 | $135.25 | $108.75 |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.02 | — | — | — | — | — | — | — | — |
| Earnings per share | −$2.42 | −$4.42 | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$2.64 | −$3.35 | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$2.64 | −$3.35 | — | — | — | — | — | — | — | — |
| Cash per share | $11.81 | $12.82 | — | — | — | — | — | — | — | — |
| Book value per share | $11.17 | $11.01 | — | — | — | — | — | — | — | — |
| Tangible book value per share | $11.17 | $11.01 | — | — | — | — | — | — | — | — |
| Capex per share | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Debt per share | — | $1.80 | — | — | — | — | — | — | — | — |
| Shares outstanding | 64.1M | 47.0M | — | — | — | — | — | — | — | — |
| Change in shares outstanding | +36.2% | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −25.2% | −59.3% | −289.2% | −124.9% | −58.8% | −80.9% | −122.7% | −75.3% | −48.1% | −43.8% |
| Return on assets (ROA) | −22.4% | −43.8% | −164.1% | −92.6% | −48.5% | −66.1% | −97.3% | −66.3% | −44.2% | −41.0% |
| Return on tangible assets | −20.0% | −34.2% | −99.1% | −117.8% | −59.9% | −50.1% | −94.1% | −57.0% | −48.6% | −32.4% |
| Free cash flow margin | — | — | — | — | −289.7% | — | — | −838.9% | −484.8% | −411.7% |
| Financial health | ||||||||||
| Total debt | — | $84.6M | $84.6M | $4.6M | $5.1M | $5.4M | $5.1M | — | — | — |
| Cash & short-term investments | $756.5M | $603.1M | $339.3M | $55.7M | $93.1M | $146.3M | $71.9M | $74.5M | $50.3M | $63.5M |
| Net debt | −$756.5M | −$518.5M | −$254.7M | −$51.1M | −$88.1M | −$140.8M | −$66.8M | −$74.5M | −$50.3M | −$63.5M |
| Debt / equity | — | 0.16 | 0.46 | 0.09 | 0.06 | 0.04 | 0.09 | — | — | — |
| Debt / assets | — | 0.14 | 0.25 | 0.07 | 0.05 | 0.03 | 0.06 | — | — | — |
| Current ratio | 13.25 | 11.26 | 10.68 | 4.25 | 4.91 | 9.11 | 4.06 | 7.49 | 9.77 | 16.75 |
| Quick ratio | 13.25 | 11.26 | 10.68 | 4.25 | 4.91 | 9.11 | 4.06 | 7.49 | 9.77 | 16.75 |
| Working capital | $719.1M | $554.4M | $309.6M | $47.6M | $78.7M | $133.3M | $56.1M | $66.4M | $49.4M | $62.5M |
| Invested capital | −$41.3M | −$729,000 | −$70.7M | −$777,000 | −$4.1M | −$993,000 | −$6.7M | −$7.1M | $38,000 | −$536,000 |
| Tangible asset value | $715.2M | $517.8M | $184.0M | $50.3M | $83.9M | $139.8M | $60.1M | $67.4M | $50.3M | $63.0M |
| Net current asset value | $715.2M | $517.8M | $183.7M | $41.4M | $72.9M | $128.0M | $51.4M | $66.4M | $49.3M | $62.3M |
| Graham net-net per share | $10.83 | $10.90 | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Capex / revenue | — | 0.0% | 0.0% | 1.6% | 3.1% | — | — | 10.9% | 11.9% | 4.6% |
| Capex / depreciation | 0.00 | 0.00 | 0.00 | 0.02 | 0.36 | 4.30 | 1.66 | 1.44 | 2.49 | 1.61 |
| Stock-based compensation / revenue | — | 5,060.2% | 2,897.9% | 305.3% | 42.9% | — | — | — | — | — |
| R&D / revenue | — | 18,373.6% | 10,102.0% | 2,515.2% | 304.5% | — | — | 944.4% | 438.3% | 392.0% |
| SG&A / revenue | — | 5,166.6% | 4,508.6% | 1,225.0% | 145.8% | — | — | — | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | 93.2 | 15.9 | — | — | 158.6 | 150.5 | 114.8 |
| Days payables outstanding | 10.2 | 295.7 | 297.8 | 371.3 | 508.3 | 607.7 | 773.1 | — | — | — |
| Cash conversion cycle (days) | — | — | — | -278.1 | -492.4 | — | — | — | — | — |
| Receivables turnover | — | — | — | 3.91 | 22.99 | — | — | 2.30 | 2.42 | 3.18 |
| Payables turnover | 35.87 | 1.23 | 1.23 | 0.98 | 0.72 | 0.60 | 0.47 | 0.00 | 0.00 | 0.00 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.03 | 0.14 | 0.00 | 0.00 | 0.06 | 0.08 | 0.09 |
| Average receivables | — | — | — | $595,000 | $815,000 | — | — | $1.7M | $2.1M | $1.5M |
| Average payables | $4.8M | $781,000 | $786,500 | $2.0M | $2.8M | $2.7M | $1.9M | $526,000 | $278,500 | $172,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from SYRE's annual financial statements (latest annual report filed February 19, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
SYRE valuation and financial ratios
Spyre Therapeutics earned a return on equity of −25.2% in fiscal 2025.
See the SYRE income statement, the SYRE chart for price history, or the SYRE stock overview for the latest quote and news.
SYRE key metrics FAQ
What is Spyre Therapeutics's return on equity?
Spyre Therapeutics's return on equity (ROE) was −25.2% in fiscal 2025: net income of -$155.2 million on average shareholders' equity of $616.5 million.
What is Spyre Therapeutics's free cash flow yield?
Spyre Therapeutics generated -$169.3 million of free cash flow in fiscal 2025, a free cash flow yield of −8.1% on its market value at year-end ($2.1 billion).
What is Spyre Therapeutics's current ratio?
Spyre Therapeutics's current ratio was 13.25 at the end of fiscal 2025: current assets were 13.25 times current liabilities.